Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679030 | 0.94 | CYP1A1 (0.41) | CYP1A1CYP1B1POLBTLR9FFAR2 | |
| SCHEMBL2678416 | 0.91 | HSD17B10 (0.36) | HSD17B10NPSR1ALDH1A1GAAKDM4E | |
| SCHEMBL2679083 | 0.88 | KCNH2 (0.41) | — | |
| SCHEMBL2678731 | 0.85 | HSD17B10 (0.39) | MAPTHSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL2679129 | 0.85 | CYP11B1 (0.41) | MAPTTSHRHSD17B10ALDH1A1GAA | |
| SCHEMBL2678414 | 0.83 | AR (0.41) | CYP2D6 | |
| SCHEMBL4469713 | 0.82 | RXFP1 (0.41) | MAPTGAALMNAMEN1KMT2A | |
| SCHEMBL2678397 | 0.82 | RXFP1 (0.43) | MAPTGAALMNAMEN1KMT2A | |
| Bromide SCHEMBL4480044 | 0.81 | RXFP1 (0.40) | MAPTGAALMNAMEN1KMT2A | |
| SCHEMBL2678549 | 0.81 | ALOX5AP (0.43) | CYP1A2CYP2E1CYP2D6CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759343-B2 | Azabicycloalkane derivatives, preparation thereof and use thereof in therapy | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| EP-2118104-B1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI SA (FR) | 2013-01-02 | — | — | EP | disclosed |
| US-20120202807-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI (FR) | 2012-08-09 | — | — | US | disclosed |
| US-8173669-B2 | Azabicycloalkane derivatives, preparation thereof and use thereof in therapy | SANOFI-AVENTIS (FR) | 2012-05-08 | — | — | US | disclosed |
| US-20100035916-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2118104-A2 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | Sanofi-Aventis (FR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008110699-A2 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202807-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | TPMT, CYP51A1, ABL1 | CYP1A1 22/4885CYP1B1 6/4885POLB 980/4885 |
| US-20100035916-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | TPMT, CYP51A1, ABL1 | CYP1A1 22/4885CYP1B1 6/4885POLB 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.